Medigene AG

General information
Medigene AG
Lochhamer Str. 11
82152 Martinsried, Bavaria

Contact person: Pamela Keck, Investor Relations / Corporate Communications
Company main phone: +49 (89) 2000330
Company main fax:  +49 (89) 2000333301
Year founded:1994
Source of foundation:Spin-off from company
Name of foundation source:Munich Gene Center
No. of employees: At this location:  64
Corporate description / mission:
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. The company's end-to-end technology platform, built on multiple proprietary and exclusive product development and product enhancement technologies, allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2000
  • Biotechnology - Therapeutics and Diagnostics
  • Cell therapy
  • Gene therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Special IP situation:
Research and development and the associated know-how is secured in 54 granted and 98 outstanding patents (2020: 47 granted and 58 outstanding patents) and forms the foundation of all our activities.
Technology used:
- PD1-41BB switch receptor
- Dendritc cells
Financing details
Market cap. / valuation:EUR 70.50M
Money raised to date:EUR 61.41M
Financing details:
Data as of 1 August 2022.
Collaborations & Clients
Partnering strategy / collaborations:
- 2seventy bio, Inc.
- BioNTech SE
- Cytovant